PHASTAR, a global specialist biometrics contract research organization (CRO), has joined Lean Life Science’s Oncology Development Programme (ODP2). The targeted programme aims to identify and accelerate novel oncology innovations into commercially-attractive assets by offering support to academics and early-stage companies.
In collaboration with top global pharma companies, Cancer Research UK’s Cancer Research Horizons, Manchester Cancer Research Centre (MCRC) and more than 20 specialist CROs, ODP2 aims to identify, de-risk and catalyse commercially viable UK-based innovations to improve diagnosis and treatment of cancer and accelerate the translation of emerging cancer research for patient benefit.
PHASTAR will be offering support from its biometrics experts, including statisticians, data scientists, data managers and programmers as part of the scheme. Its commitment to ODP2 mirrors its existing PHASTAR Cares programme – a comprehensive, corporate Environmental, Social, and Governance (ESG) strategy which offers pro bono support to charities.
“At PHASTAR we believe we have a duty to do our part in enabling innovation and improving outcome for patients around the world. ODP2 offers an opportunity for individuals and newer companies who do not necessarily have the benefit of a wealth of expertise to get drugs developed in the clinical trial setting, offering new oncology treatment options for patients.” comments Andrew MacGarvey, CEO, Phastar.
ODP2 is seeking applications from academics and early-stage companies with a defined oncology-focused innovation. It will give the next big UK-based breakthroughs in oncology access to bespoke expert scientific review, clinical study design, biometric data, technical gap analysis, financial and business value modelling, and integrated project planning.
Up to 100 oncology innovations will be selected by the Programme Faculty Panel, to participate in part one of the programme – a fully immersive one-day virtual masterclass on Friday 13th January 2023. Hearing directly from pharma, investors and other key industry experts, participants will gain insights into how oncology assets are assessed and developed. Participants will also receive a detailed overview of the programme and hear the first-hand experiences of previous participants.
Part two of ODP2 is a three-day deep dive into the highly successful Lean Life Science approach to developing oncology assets and securing investment and is an opportunity to engage directly with pharma and CRO experts.
Part three, by application, will see selected participants work closely with the partners to create and validate the integrated plans necessary to ensure successful development and attract potential funding.
“I’m very pleased to be launching ODP2 in collaboration with Cancer Research UK, and to be officially announcing the opening of the application period. I am excited to drive this second oncology development programme. We have a proven approach which, in collaboration with our experienced sector experts, accelerates development of all participants’ innovations into more commercially viable and attractive investment opportunities.” – Ned Wakeman, CEO of Lean Life Science
PHASTAR has recently announced its Pro Bono scheme for eligible charities – PHASTAR Cares.